Zydus Lifesciences Ltd - ZYDUS LIFESCI. Share Price

Sector: Pharmaceuticals | ISIN: INE010B01027
₹ 1,085.90 (0.49%) icon23 May, 2024, 12:19:59 PM
Open
₹ 1,090.00
Prev. Close
₹ 1,080.65
Turnover(lac)
₹ 0.00
Day's High
₹ 1,105.00
Day's Low
₹ 1,077.80
52 Wk High
₹ 1,172.50
52 Wk Low
₹ 498.85
Book Value
₹ 169.75
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 109,266.95
P/E
31.41
EPS
34.27
Div. Yield
0.28

Zydus Lifesciences Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/23/2024 12:19:59 PM

    ₹ 1085.9 5.25 0.49
  • Open
  • ₹ 1,090
  • Prev. Close
  • ₹ 1,080.65
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 1,105
  • Day's Low
  • ₹ 1,077.8
  • 52 Week's High
  • ₹ 1,172.5
  • 52 Week's Low
  • ₹ 498.85
  • Book Value
  • ₹ 169.75
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 109,266.95
  • P/E
  • 31.41
  • EPS
  • 34.27
  • Divi. Yield
  • 0.28

Zydus Lifesciences Ltd Corporate Actions

09 May , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jan , 2024

12:00 AM

29 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Oct , 2023

12:00 AM

18 May , 2023

12:00 AM

AGM

Announcement date: 18 May , 2023

View Details

31 Jul , 2023

12:00 AM

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 May , 2023

12:00 AM

Dividend

Dividend amount: 6
Announcement date: 18 May , 2023

View Details

No Record Found


Zydus Lifesciences Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Zydus Lifesciences Ltd SHAREHOLDING SNAPSHOT
23 May , 2024 | 12:38 PM

PROMOTER - TOTAL74.98%

Indian: 74.98%

Foreign: 0%

NON-PROMOTER - TOTAL 25.02%

Institutions: 18.36%

Non-Institutions: 6.66%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Zydus Lifesciences Ltd FINANCIALS

View Profit & Loss Graph

Zydus Lifesciences Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Zydus Lifesciences Ltd

  • Pankaj R Patel
  • Chairman (Non-Executive)
  • Sharvil P Patel
  • Managing Director
  • Mukesh M Patel
  • Director
  • Nitin Raojibhai Desai
  • Independent Director
  • Dharmishta N Rawal
  • Independent Director
  • Apurva S Diwanji
  • Independent Director
  • Ganesh N Nayak
  • Executive Director
  • Bhadresh K Shah
  • Independent Director
  • Dhaval N Soni
  • Company Sec. & Compli. Officer
  • Akhil A. Monappa
  • Independent Director
  • Upasana Konidela.
  • Independent Director

Summary

Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) is one of the leading innovation driven pharmaceutical companiesin India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing,marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, includingbiosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products. The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh.Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996. The Companys operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the Company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative... Read More


Reports by Zydus Lifesciences Ltd


Reports by Zydus Lifesciences Ltd

Company FAQ

No Record Found